The report offers in-depth analysis of the global CRISPR And CRISPR-Associated (Cas) Genes market taking into account market dynamics, segmentation, geographical expansion, competitive landscape, and various other key aspects. The market analysts who have prepared the report have thoroughly studied the global CRISPR And CRISPR-Associated (Cas) Genes market and have offered reliable and accurate data. They understand the needs of the industry and the clients, which makes it easy for them to focus on the aspects, which the end users have been looking for.
Major Key Player Operating in this Report are: Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon
Get the Sample of this [emailprotected]https://www.qyresearch.com/sample-form/form/1434599/global-crispr-and-crispr-associated-cas-genes-market
The report analyses the current trends, growth opportunities, competitive pricing, restraining factors, and boosters that may have an impact on the overall dynamics of the global CRISPR And CRISPR-Associated (Cas) Genes market. The report analytically studies the microeconomic and macroeconomic factors affecting the global CRISPR And CRISPR-Associated (Cas) Genes market growth. New and emerging technologies that may influence the global CRISPR And CRISPR-Associated (Cas) Genes market growth are also being studied in the report.
The market experts also offer best possible service and recommendations to the customers. This report can surely act as a resourceful tool for the companies, investors, and executives to become equipped and take sound and effective decisions. This will eventually help them stay ahead of the curve and gain maximum profits.
Segmental Analysis
The analysts have thoroughly studied all the segments including product type, application, and region. The report provides comprehensive analysis of the contribution of the segments to the overall market size. Moreover, the experts have predicted each segments growth potential, which may assist the clients to plan their future activities. The regional analysis mentioned in the report gives a clear cut understanding to the market participants regarding the present as well as future scenario of the global CRISPR And CRISPR-Associated (Cas) Genes market in key regions.
Segment By Type:
, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering
Segment By Application:
, Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes Key Players: The Key manufacturers that are operating in the
Competitive Landscape
It is important for every market participant to be familiar with the competitive scenario in the global CRISPR And CRISPR-Associated (Cas) Genes industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.
Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon
Key queries related to the global CRISPR And CRISPR-Associated (Cas) Genes market addressed in the report:
While planning the strategic initiatives, market participants come across various questions and uncertainties. This report resolves various queries that most market players have regarding the global CRISPR And CRISPR-Associated (Cas) Genes market. Does the global CRISPR And CRISPR-Associated (Cas) Genes market have growth potential? What are the growth opportunities for the new entrants in the global CRISPR And CRISPR-Associated (Cas) Genes market? Who are the leading manufacturers operating in the global CRISPR And CRISPR-Associated (Cas) Genes market? Will they maintain their dominance in future? What are the key strategies that market players may adopt to strengthen their presence in the global CRISPR And CRISPR-Associated (Cas) Genes market? How will the competitive scenario undergo a change in years to come? What are the emerging trends that may influence the growth of the global CRISPR And CRISPR-Associated (Cas) Genes market? What are the factors that may hamper the global CRISPR And CRISPR-Associated (Cas) Genes market growth in the years ahead? Which product type segment is expected to exhibit promising growth in the near future? What application is anticipated to grab a major share in the global CRISPR And CRISPR-Associated (Cas) Genes market? Which region is likely to emerge as a lucrative regional market in the forthcoming years?
Get Customized Report in your Inbox within 24 hours @https://www.qyresearch.com/customize-request/form/1434599/global-crispr-and-crispr-associated-cas-genes-market
CRISPR And CRISPR-Associated (Cas) Genes Market Table of Content
Table of Contents 1 CRISPR And CRISPR-Associated (Cas) Genes Market Overview1.1 Product Overview and Scope of CRISPR And CRISPR-Associated (Cas) Genes1.2 CRISPR And CRISPR-Associated (Cas) Genes Segment by Type1.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Growth Rate Comparison by Type (2021-2026)1.2.2 Genome Editing1.2.3 Genetic engineering1.2.4 gRNA Database/Gene Librar1.2.5 CRISPR Plasmid1.2.6 Human Stem Cells1.2.7 Genetically Modified Organisms/Crops1.2.8 Cell Line Engineering1.3 CRISPR And CRISPR-Associated (Cas) Genes Segment by Application1.3.1 CRISPR And CRISPR-Associated (Cas) Genes Sales Comparison by Application: 2020 VS 20261.3.2 Biotechnology Companies1.3.3 Pharmaceutical Companies1.3.4 Academic Institutes1.3.5 Research and Development Institutes1.4 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Estimates and Forecasts1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue 2015-20261.4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales 2015-20261.4.3 CRISPR And CRISPR-Associated (Cas) Genes Market Size by Region: 2020 Versus 2026 2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Competition by Manufacturers2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Manufacturers (2015-2020)2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2015-2020)2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Average Price by Manufacturers (2015-2020)2.4 Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Sites, Area Served, Product Type2.5 CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Situation and Trends2.5.1 CRISPR And CRISPR-Associated (Cas) Genes Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key CRISPR And CRISPR-Associated (Cas) Genes Players (Opinion Leaders) 3 CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario by Region3.1 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.3.1 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.3.2 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.4.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.4.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Region3.5.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region3.5.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.6.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.6.2 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.7.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.7.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global CRISPR And CRISPR-Associated (Cas) Genes Historic Market Analysis by Type4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Type (2015-2020)4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2015-2020)4.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price Market Share by Type (2015-2020)4.4 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global CRISPR And CRISPR-Associated (Cas) Genes Historic Market Analysis by Application5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Application (2015-2020)5.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2015-2020)5.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price by Application (2015-2020) 6 Company Profiles and Key Figures in CRISPR And CRISPR-Associated (Cas) Genes Business6.1 Caribou Biosciences6.1.1 Corporation Information6.1.2 Caribou Biosciences Description, Business Overview and Total Revenue6.1.3 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.1.4 Caribou Biosciences Products Offered6.1.5 Caribou Biosciences Recent Development6.2 Addgene6.2.1 Addgene CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.2.2 Addgene Description, Business Overview and Total Revenue6.2.3 Addgene CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.2.4 Addgene Products Offered6.2.5 Addgene Recent Development6.3 CRISPR THERAPEUTICS6.3.1 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.3.2 CRISPR THERAPEUTICS Description, Business Overview and Total Revenue6.3.3 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.3.4 CRISPR THERAPEUTICS Products Offered6.3.5 CRISPR THERAPEUTICS Recent Development6.4 Merck KGaA6.4.1 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.4.2 Merck KGaA Description, Business Overview and Total Revenue6.4.3 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.4.4 Merck KGaA Products Offered6.4.5 Merck KGaA Recent Development6.5 Mirus Bio LLC6.5.1 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.5.2 Mirus Bio LLC Description, Business Overview and Total Revenue6.5.3 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.5.4 Mirus Bio LLC Products Offered6.5.5 Mirus Bio LLC Recent Development6.6 Editas Medicine6.6.1 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.6.2 Editas Medicine Description, Business Overview and Total Revenue6.6.3 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.6.4 Editas Medicine Products Offered6.6.5 Editas Medicine Recent Development6.7 Takara Bio USA6.6.1 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.6.2 Takara Bio USA Description, Business Overview and Total Revenue6.6.3 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.4.4 Takara Bio USA Products Offered6.7.5 Takara Bio USA Recent Development6.8 Thermo Fisher Scientific6.8.1 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.8.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue6.8.3 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.8.4 Thermo Fisher Scientific Products Offered6.8.5 Thermo Fisher Scientific Recent Development6.9 Horizon Discovery Group6.9.1 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.9.2 Horizon Discovery Group Description, Business Overview and Total Revenue6.9.3 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.9.4 Horizon Discovery Group Products Offered6.9.5 Horizon Discovery Group Recent Development6.10 Intellia Therapeutics6.10.1 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.10.2 Intellia Therapeutics Description, Business Overview and Total Revenue6.10.3 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.10.4 Intellia Therapeutics Products Offered6.10.5 Intellia Therapeutics Recent Development6.11 GE Healthcare Dharmacon6.11.1 GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.11.2 GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes Description, Business Overview and Total Revenue6.11.3 GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.11.4 GE Healthcare Dharmacon Products Offered6.11.5 GE Healthcare Dharmacon Recent Development 7 CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Cost Analysis7.1 CRISPR And CRISPR-Associated (Cas) Genes Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of CRISPR And CRISPR-Associated (Cas) Genes7.4 CRISPR And CRISPR-Associated (Cas) Genes Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 CRISPR And CRISPR-Associated (Cas) Genes Distributors List8.3 CRISPR And CRISPR-Associated (Cas) Genes Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of CRISPR And CRISPR-Associated (Cas) Genes by Type (2021-2026)10.1.2 Global Forecasted Revenue of CRISPR And CRISPR-Associated (Cas) Genes by Type (2021-2026)10.2 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of CRISPR And CRISPR-Associated (Cas) Genes by Application (2021-2026)10.2.2 Global Forecasted Revenue of CRISPR And CRISPR-Associated (Cas) Genes by Application (2021-2026)10.3 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of CRISPR And CRISPR-Associated (Cas) Genes by Region (2021-2026)10.3.2 Global Forecasted Revenue of CRISPR And CRISPR-Associated (Cas) Genes by Region (2021-2026)10.4 North America CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.5 Europe CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.6 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.7 Latin America CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.8 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 DisclaimerAbout Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.
See more here:
- IOM not webcast today. Why Not? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- National Academies skeptical at Best. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Some Confusion Exists [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Why DTC Genomics IS Medicine. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- First Mari, Now Linda. Who's next? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Is it true? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Re-Reviewing the National Academies [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- The problem with nonclinicians....... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Crazy Night of Emails to Government [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Adrienne Carlson's Personalized Medicine. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Tell Me, How do you feel now? Sherpa's RX [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- This Just In. 23andMe to go to GPs. I love my readers!! [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Sorry so long away [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- 2D6 Rears its ugly head..... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Ok, Fine, Back to Plavix [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Kaiser a protoype for Collins' Aim [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- A few months late to the party.... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Stated Another Way....... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Excuse Me? Harvard and Navigenics? WTF? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Follow up to Yesterday's WTF? Harvard, Navi? and Pfizer??? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Did you get your kit? Thanks Dr. Rob from MedCo [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Gluco...Wha? Parkinson's Disease and Glucocerebrosidase mutations. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Away and now back, What did I miss???? 23andme layoffs? Selling Genomes for cheap up next! [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Change IS Needed. I agree with William, sometimes. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Good Enough Science? Apparently so at 23andme [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Long QT Syndrome, location matters [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Congratulations Generation Health. Nice pick up! [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- An argument 23andSerge can't win...23andme but not medicine [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Stop. Breathe. Repeat. An analysis of the direction of DTC Genomics Field. [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Hey DTC genomics, Stay Private, Stay Alive, Go Public and Die [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- You can't have it both way. Either scared your genome is sold off or not. [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- 15 Days Away Gives Time for Perspective. [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- What about the SACGHS registry? Another missed opportunity? [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- AJHG is in and my Favorite Muin is in it! But He Is NOT the Father! [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Navigenics for 23andMe prices? [Last Updated On: December 18th, 2009] [Originally Added On: December 18th, 2009]
- Lp(a) Maybe there's something there that wasn't there before? [Last Updated On: December 24th, 2009] [Originally Added On: December 24th, 2009]
- Another Year, Another Bankruptcy [Last Updated On: December 31st, 2009] [Originally Added On: December 31st, 2009]
- 5 Technologies going bye bye in this decade? [Last Updated On: January 6th, 2010] [Originally Added On: January 6th, 2010]
- Hackers, HITECH and HIPAA in DTC Genomics, Oh My! [Last Updated On: January 7th, 2010] [Originally Added On: January 7th, 2010]
- Personal Genomics Flop.....big Belly Flop! [Last Updated On: January 8th, 2010] [Originally Added On: January 8th, 2010]
- Gotta Love It. Even the daycare....... [Last Updated On: January 11th, 2010] [Originally Added On: January 11th, 2010]
- Congratulations Navigenics. You ARE a clinical lab! Uh-Oh... [Last Updated On: January 12th, 2010] [Originally Added On: January 12th, 2010]
- CETP, Jewish Centenarians and Alzheimers [Last Updated On: January 14th, 2010] [Originally Added On: January 14th, 2010]
- Enter the "Not" DTC Genomics Rep [Last Updated On: January 17th, 2010] [Originally Added On: January 17th, 2010]
- Why Dr. Vanier's Navigenics appointment is good for PM [Last Updated On: January 22nd, 2010] [Originally Added On: January 22nd, 2010]
- Holy Crap! MedCo Follows in CVS footsteps [Last Updated On: February 3rd, 2010] [Originally Added On: February 3rd, 2010]
- FDA, Warfarin, still not as sexy to me. [Last Updated On: February 5th, 2010] [Originally Added On: February 5th, 2010]
- Hype, Hype, Hype from a single study. [Last Updated On: February 11th, 2010] [Originally Added On: February 11th, 2010]
- I love my readers, even Renata M! [Last Updated On: February 17th, 2010] [Originally Added On: February 17th, 2010]
- How can insurers use DTC genomics to profile? [Last Updated On: February 17th, 2010] [Originally Added On: February 17th, 2010]
- 9p21.....ahem. Paynter et.al. Smackdown. Again. [Last Updated On: February 18th, 2010] [Originally Added On: February 18th, 2010]
- Hey! It's Pete Hulick! Are you Going to GET? [Last Updated On: February 19th, 2010] [Originally Added On: February 19th, 2010]
- I was wrong......AHEM [Last Updated On: February 28th, 2010] [Originally Added On: February 28th, 2010]
- G2C2, finally a tool for genomic education! [Last Updated On: March 2nd, 2010] [Originally Added On: March 2nd, 2010]
- Just 4 million? What 23andMe is worth. [Last Updated On: March 5th, 2010] [Originally Added On: March 5th, 2010]
- What a difference a year makes [Last Updated On: March 9th, 2010] [Originally Added On: March 9th, 2010]
- ........DTC Genomic Medicine? [Last Updated On: March 12th, 2010] [Originally Added On: March 12th, 2010]
- The FDA, 2c19 and the ACC [Last Updated On: March 13th, 2010] [Originally Added On: March 13th, 2010]
- The problem with Comparative Whole Genomics...... [Last Updated On: March 13th, 2010] [Originally Added On: March 13th, 2010]
- BRCA testing by 23andME is the same as Myriad Genetics. [Last Updated On: March 15th, 2010] [Originally Added On: March 15th, 2010]
- The Argument Against DTC Genomics Marketing and such [Last Updated On: March 16th, 2010] [Originally Added On: March 16th, 2010]
- A moment of Clarity. Some DTCG is not bad. [Last Updated On: March 18th, 2010] [Originally Added On: March 18th, 2010]
- SNPs for breast cancer risk? It Depends. [Last Updated On: March 18th, 2010] [Originally Added On: March 18th, 2010]
- How can MDVIP use Navigenics Test for Medicine? [Last Updated On: March 18th, 2010] [Originally Added On: March 18th, 2010]
- Why did P&G invest in Navigenics? [Last Updated On: March 23rd, 2010] [Originally Added On: March 23rd, 2010]
- PGx in DTCG? Doesn't stand up to Useful testing. [Last Updated On: March 25th, 2010] [Originally Added On: March 25th, 2010]
- End of Gene Patents? [Last Updated On: March 29th, 2010] [Originally Added On: March 29th, 2010]
- Sherpa Accepting Chief Medical Officership [Last Updated On: April 3rd, 2010] [Originally Added On: April 3rd, 2010]
- The Rumors of My Death........ [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- Happy DNA Day! [Last Updated On: April 25th, 2010] [Originally Added On: April 25th, 2010]
- 99 USD, DNA day and patient letters [Last Updated On: April 25th, 2010] [Originally Added On: April 25th, 2010]
- 2C19, Navigenics and Clinical Reality. [Last Updated On: May 1st, 2010] [Originally Added On: May 1st, 2010]
- Coriell Personalized Medicine Collaborative rising [Last Updated On: May 7th, 2010] [Originally Added On: May 7th, 2010]
- Personal Genomes in Clinical Care. Quake paper is a waste! [Last Updated On: May 11th, 2010] [Originally Added On: May 11th, 2010]
- Personal Genomes in Clinical Care. Quake paper Falls Short! [Last Updated On: May 13th, 2010] [Originally Added On: May 13th, 2010]
- Last post edited by Drew [Last Updated On: May 13th, 2010] [Originally Added On: May 13th, 2010]
- GateKeeper? FCUK U! [Last Updated On: May 13th, 2010] [Originally Added On: May 13th, 2010]
- GateKeeper? F! U! [Last Updated On: May 15th, 2010] [Originally Added On: May 15th, 2010]
- Potential of genomic medicine, LOST [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- How Bad Can a House Investigation be for DTC Genomics? [Last Updated On: May 20th, 2010] [Originally Added On: May 20th, 2010]